Issue 4/2023
Content (11 Articles)
External Evaluation of Population Pharmacokinetic Models for Precision Dosing: Current State and Knowledge Gaps
Mehdi El Hassani, Amélie Marsot
Clinical Pharmacokinetics and Pharmacodynamics of CSL112
Luis Ortega-Paz, Salvatore Giordano, Davide Capodanno, Roxana Mehran, C. Michael Gibson, Dominick J. Angiolillo
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
T. Y. J. Appeldoorn, T. H. Oude Munnink, L. M. Morsink, M. N. Lub-de Hooge, D. J. Touw
Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients
Eko Setiawan, Menino Osbert Cotta, Mohd-Hafiz Abdul-Aziz, Doddy Widjanarko, Hernycane Sosilya, Dwi Lily Lukas, Steven C. Wallis, Suzanne Parker, Jason A. Roberts
Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer
Neang S. Ly, Jing Li, Raffaella Faggioni, Lorin K. Roskos, Marcia S. Brose
Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
Eunsol Yang, Sang Chun Ji, In-Jin Jang, SeungHwan Lee
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist
Islam Younis, Elijah Weber, Cara Nelson, Brian J. Kirby, Gong Shen, Deqing Xiao, Timothy R. Watkins, Ahmed A. Othman
Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn’s Disease and Ulcerative Colitis
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Mong-Jen Chen, Insa Winzenborg, Sven Mensing, Jonas Blaes, Tobias Haslberger, Loic Laplanche, Ingeborg Dreher, Nael M. Mostafa
Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects
Marloes van Hout, Pablo Forte, Thomas B. Jensen, Cristina Boschini, Tine A. Bækdal
Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
Mikkel Askjær Agersnap, Kim Sonne, Kim Mark Knudsen, Wladyslaw Sulowicz
Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
Mikkel Askjær Agersnap, Kim Sonne, Kim Mark Knudsen, Wladyslaw Sulowicz